Bipolar Depression Pipeline Expands With 10+ Therapies in Development Across 8+ Companies

The bipolar depression treatment landscape is expanding with 8+ active companies developing 10+ pipeline therapies, according to a pipeline analysis covering clinical and nonclinical stage products. The market is anticipated to increase during the forecast period from 2026 to 2036, driven by the launch of emerging therapies and rising healthcare spending across the United States, EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

On February 03, 2026, Xenon Pharmaceuticals Inc. announced a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of azetukalner in adult participants diagnosed with bipolar I or II disorder who are currently in a depressive episode (bipolar depression).

On February 04, 2026, AbbVie conducted a study enrolling around 380 participants ages 10-17 years with bipolar I disorder in approximately 60 sites worldwide. The study assigns participants to 1 of 2 treatment arms, with a 1 in 2 chance of assignment to placebo.

On February 17, 2026, University of Sao Paulo initiated a study to evaluate the efficacy of combining lacosamide as an augmentation treatment to first- or second-line medication treatments in moderate to severe major depressive episodes of treatment-resistant BD I and II (failure of at least two adequate treatments during the current episode). The double-blind, randomized, parallel-group pilot study will compare the enhancement of treatment with lacosamide and placebo over a duration of 12 weeks. Forty subjects aged between 18 and 65 years with a diagnosis of BD (I or II) in a moderate or severe major depressive episode, despite the use of first- or second-line treatments, will be selected.

Promising therapies in the pipeline include Azetukalner (Xenon Pharmaceuticals), Elunetirom (ABX-002) (Autobahn Therapeutics), ABBV-932 and Icalcaprant (ABBV-1354) (AbbVie), ALTO-100 (Alto Neuroscience), NRX-101 (NRx Pharmaceuticals), LB-102 (LB Pharmaceuticals), and others. Additional pipeline candidates include KarXT, AL001, RP5063, RAP 219, Aripiprazole 2-month injectable, CB03-154, and 4MT 2001.

NRX-101 is a fixed-dose combination of D-Cycloserine and Lurasidone. NRX-101 is part of NRx Pharma's investigational medicine regimen of NRX-100 (ketamine) and NRX-101. The FDA has granted the combination therapy a Breakthrough Therapy Designation (BTD) for the treatment of severe bipolar depression in patients with acute suicidal ideation and behavior (ASIB), after initial stabilization with ketamine or other effective therapy. Currently the drug is in Phase III trial for Bipolar Depression. NRX-101 is a patented, oral fixed-dose combination of two FDA-approved drugs: D-cycloserine, an NMDA receptor modulator at certain dosage ranges; and Lurasidone, a 5-HT2a receptor antagonist.

The United States accounted for the largest bipolar depression treatment market size in 2025, compared to other major markets. Bipolar depression has the highest prevalence among diagnosed cases in the US within the 18–25 age group, affecting approximately 3.40% of this population. The diagnosed prevalent cases of bipolar depression are expected to increase during the forecast period due to improved diagnostic tools, genetic predisposition research, and stress-related lifestyle changes.

The pharmacological treatment of bipolar depression primarily involves mood stabilizers like lithium and valproate, along with atypical antipsychotics such as quetiapine, lurasidone, and the olanzapine/fluoxetine combination. Newer-generation antipsychotics with improved safety profiles and fewer side effects are gaining market traction. Approved treatments for bipolar depression include FANAPT, marketed by Vanda Pharmaceuticals, and VRAYLAR, marketed by AbbVie, among others.

Despite available options, substantial unmet needs persist due to suboptimal response, delayed diagnosis, and poor long-term adherence. Current therapies present safety concerns, including metabolic and cognitive side effects. Emerging therapies targeting novel pathways, including dopamine and glutamate modulation, offer hope for more effective, personalized treatments.

Advances in diagnostic tools, including imaging, biomarkers, and digital mood tracking tools, enhance early detection and personalized treatment planning. The total bipolar depression treatment market size is expected to grow positively by 2036 in the leading markets.